Wegovy label adds warning that the FlexTouch pen must never be shared between patients
Wegovy's label now formally prohibits sharing the four-dose FlexTouch pen, a detail that bears on households, clinics and anyone handling a pen prescribed to someone else.
The Wegovy prescribing information now carries a warning that the multi-dose Wegovy FlexTouch pen must never be shared between patients, even if the needle is changed [1]. The warning is new in the label revision dated June 2026 and appears in the Warnings and Precautions section as 5.11 [1][2]. The DailyMed listing for Wegovy, which carries the same label text, was updated June 18, 2026 [2].
What the label describes
FlexTouch is a multi-dose, single-patient-use pen: a 9.6 mg/3 mL (3.2 mg/mL) semaglutide solution that delivers four 2.4 mg/0.75 mL doses [1][2]. The usual recommended maintenance dosage of Wegovy injection is 2.4 mg once weekly [1][2], so one FlexTouch pen holds four weekly doses at that strength.
The label's Recent Major Changes list records the addition as "Never Share WEGOVY FlexTouch Between Patients (5.11) ... 06/2026," alongside other recent updates: Indications and Usage (08/2025, 12/2025), Dosage and Administration (08/2025, 12/2025, 03/2026), Acute Kidney Injury Due to Volume Depletion (08/2025), and Severe Gastrointestinal Adverse Reactions (10/2025) [1][2].
The label does not say what prompted the new warning, and it describes no infections or other incidents tied to pen sharing [1][2]. It also does not state whether similar never-share language applies to Wegovy's other forms. Those include single-dose pens of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, and 7.2 mg per 0.75 mL (Wegovy HD), single-dose syringes, and tablets of 1.5 mg, 4 mg, 9 mg, and 25 mg [1][2]. Whether FlexTouch is currently reaching pharmacies is not addressed in the label [1][2].
The two label copies also disagree on one unrelated date: the removal of the Suicidal Behavior and Ideation warning is listed as 01/2026 in one version and 02/2026 in the other [1][2].
Why it matters for patients
A pen that holds four doses is meant to be used by one person for one month. Because the needle attaches to the same device that holds the drug, a shared pen means a device that has been used on one person's body is then used on another. The label's instruction is explicit that changing the needle does not make sharing acceptable [1][2].
The practical effect is narrow but concrete. Someone who has been prescribed Wegovy through a household member's pen, a workplace, a clinic, or any other arrangement where one device serves more than one person is now doing something the label directly prohibits [1][2]. The same label separately states that using Wegovy alongside another semaglutide product or any other GLP-1 receptor agonist is not recommended [1][2], which is a separate restriction from the sharing warning and covers a different situation.
Nothing in the label suggests the drug itself has changed, or that the FlexTouch doses, strength, or dosing schedule have been altered [1][2]. The change is to the written instructions that come with the product.
Wegovy also carries a boxed warning about thyroid C-cell tumors seen in rodents, with human relevance undetermined, and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [1][2]. That warning is unchanged by the June 2026 revision [1][2].
What happens next
No timeline has been reported for extending the never-share language to Wegovy's single-dose pens, syringes, or tablets, and no further regulatory action beyond the June 2026 label revision has been disclosed [1][2]. The next visible step, if any, would be the appearance of the warning on packaging or in patient-facing materials, which the label does not address [1][2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.